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Abstract
Background: Alzheimer’s disease (AD) is characterized by a neurodegenerative progression that alters cognition. On a
phenotypical level, cognition is evaluated by means of the MiniMental State Examination (MMSE) and the post-morten
examination of Neurofibrillary Tangle count (NFT) helps to confirm an AD diagnostic. The MMSE evaluates different aspects
of cognition including orientation, short-term memory (retention and recall), attention and language. As there is a normal
cognitive decline with aging, and death is the final state on which NFT can be counted, the identification of brain gene
expression biomarkers from these phenotypical measures has been elusive.
Methodology/Principal Findings: We have reanalysed a microarray dataset contributed in 2004 by Blalock et al. of 31
samples corresponding to hippocampus gene expression from 22 AD subjects of varying degree of severity and 9 controls.
Instead of only relying on correlations of gene expression with the associated MMSE and NFT measures, and by using
modern bioinformatics methods based on information theory and combinatorial optimization, we uncovered a 1,372-probe
gene expression signature that presents a high-consensus with established markers of progression in AD. The signature
reveals alterations in calcium, insulin, phosphatidylinositol and wnt-signalling. Among the most correlated gene probes with
AD severity we found those linked to synaptic function, neurofilament bundle assembly and neuronal plasticity.
Conclusions/Significance: A transcription factors analysis of 1,372-probe signature reveals significant associations with the
EGR/KROX family of proteins, MAZ, and E2F1. The gene homologous of EGR1, zif268, Egr-1 or Zenk, together with other
members of the EGR family, are consolidating a key role in the neuronal plasticity in the brain. These results indicate a
degree of commonality between putative genes involved in AD and prion-induced neurodegenerative processes that
warrants further investigation.
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Introduction
Gomez Ravetti and Moscato have recently shown that the
abundance of five proteins, within a panel that also measured
other 115 cytokines and growth factors, can be used to predict the
development of clinical Alzheimer’s Disease (AD) [1]. The
biomarker molecular signature is composed of IL-1a, TNF-a,
IL-3, EGF and G-CSF and has the same level of specificity and
sensitivity as the original 18-protein signature proposed by Ray
et al. [2] in late 2007, who introduced this important dataset in the
literature. In the original work, Ray et al. had employed the
abundance of 120 signalling proteins in plasma to obtain their 18-
protein signature set. They used a training set of 83 samples to
identify patients that progressed to AD in two to six years. The
proposed 5-protein signature has an average of 96% accuracy in
predicting clinical AD but it is still linked to the joint measurement
of 120 protein abundances.
In this paper, we are revisiting the quest of finding biomarkers of
AD. However, this time we aim at finding biomarkers in
hippocampus tissue samples which would complement the results
of the previous studies on plasma biomarkers. This study will now
give a different perspective on the progression of the disease,
keeping a systems biology and functional genomics approach.
Towards this end, we have chosen to rely on an informative
experimental design and dataset contributed by Blalock et al. [3].
We believe that their dataset may help us to locate, either directly
or indirectly, other biomarkers of interest that could eventually be
detectable in plasma.
Blalock et al. analysed samples from 35 patients with four
different levels of AD severity: control, incipient, moderate and
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10153severe; for this paper we used only 31 samples for which
information is available online. The label assigned to each sample
(its ‘‘level of severity’’) was decided after considering two important
scores, those provided by the MiniMental State Examination (MMSE)
and the Neurofibrillary Tangle count (NFT). The MMSE score is
based on a questionnaire that aims at measuring the level of
cognitive impairment of a patient. The questions are aimed at
evaluating different aspects of cognition, such as orientation, short-
term memory (retention and recall), attention and language. A
normal score can range from 24 to 30, mild cognitive impairment
on the interval 20 to 23, moderate AD between 10 to 19, and the
rest (from 0 to 9) are all considered severe AD cases.
As previously mentioned, Blalock et al. [3] also used the NFT
score to assign a severity label to each sample. The NFT score is a
well established method for the neuropathological diagnosis of AD
[4]. The score is usually based on the average counts of
neurofibrilary tangles considering different regions of the brain.
A NFT score is a recognised indicator of AD, nevertheless, it is not
completely effective as there is evidence that NFTs were also
identified in healthy aging brains [5,6,7,8].
The analysis by Blalock et al. [3] focused on the identification of AD-
related genes (ADG) and incipient ADG (IADG) using a methodology
based on the correlation of the genes with NFT and MMSE scores. In
turn, they identified putative biological processes and signalling
pathways that are significantly present in those gene lists. Our analysis
takes a different direction. While still based on the same dataset, we are
attempting to map the progression of the disease, finding biomarkers
linked to disease severity, by identifying the genes associated with the divergence
of the gene expression profile of a sample with the gene expression average profile of the
Figure 1. This plot illustrates that the third step of our
methodology, the use of the Jensen-Shannon divergence, does
not appear to give an interesting separation of the samples in
the absence of a previous feature selection step. For this graph,
all 22,215 genes were considered in the calculation of the average
profile of the samples in the ‘‘Control’’ and ‘‘Severe AD’’ classes. The
square root of the Jensen-Shannon divergences to the ‘‘Control’’ and
‘‘Severe AD’’ average profile are computed, respectively giving, for each
sample, its x and y coordinates in this plot. Observe that most of the
‘‘Control’’ samples have values lower than 0.12, with two exceptions.
This result is expected, as the probability distribution function of the
‘‘Control’’ class was used. However, most of the samples from AD
patients (having either ‘‘Incipient AD’’, ‘‘Moderate’’ or ‘‘Severe’’ labels),
show a divergence with the Control average gene expression profile.
Figure 2 shows the important contribution provided by the feature
selection step.
doi:10.1371/journal.pone.0010153.g001
Figure 2. This plot illustrates that after application of the feature
selection steps, followed by the computation of the gene
expression profile’s average profile of the samples in the
‘‘Control’’ and ‘‘Severe AD’’ classes (now on a set of 1,372
probes), the samples are now more clearly separated. Here, all
‘‘Control’’ samples have the square root of the Jensen-Shannon divergences
to the average gene expression of the ‘‘Control’’ samples (x-coordinate)
smaller than 0.12 (almost all severe AD have x-coordinates greater than
0.15).Inadditiontothat,mostsampleslabelled‘‘SevereAD’’arelocatedon
the same region. Both results are expected. However, it is interesting that
in this (x,y)-plot most samples that are labelled ‘‘Incipient AD’’ or
‘‘Moderate AD’’ seem to ‘‘bridge’’ between the regions that have most
ofthe‘‘Control’’samples andtheregionthat havemost ofthe‘‘SevereAD’’
group. This result is interesting as no samples from ‘‘Incipient AD’’ nor
‘‘Moderate AD’’ have been used in the first three steps of our
methodology. In essence, the work is a ‘‘test set’’ indicating that it is
reasonable to expect that some genes in the genetic signature of 1,372
probes have information about a putative ‘‘progression’’ trend of the
disease, from the ‘‘Control’’ to the ‘‘Severe AD’’ profile. In what follows,
correlations across all the samples with these divergences are used as a
method to try to identify those gene profiles that are most correlated with
the progression from ‘‘Control’’ to ‘‘Severe AD’’.
doi:10.1371/journal.pone.0010153.g002
Figure 3. This plot shows the MMSE scores as a function of the
square root of the Jensen-Shannon divergences to the average
gene expression of the ‘‘Control’’ samples. ‘Incipient AD’ samples,
although having a lower value for their MMSE score, still do not show a
dramatic change in their x-coordinates compared to the ‘Control’ samples.
‘Moderate AD’ samples appear to be more scattered, with some of them
already having a significant divergence from the ‘Control’ average profile.
doi:10.1371/journal.pone.0010153.g003
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that seem to best correlate with the ‘‘convergence’’ to the average
profile of the ‘‘AD Severe’’ group of samples. The difference between
Blalock et al.’s [3] methodological approach to data analysis and ours is
very important. We aim to uncover genes that correlate with the
divergence of the gene expression profiles, instead of relying only on
correlations with the NFT and MMSE values.
Our objective is to uncover genes which are highly correlated to
the progression of the disease. With this objective in mind, we will
concentrate the first part of our analysis on the two most extremely
separated classes, the sets of samples that have been labelled as
‘‘Control’’ and those labelled ‘‘AD Severe’’. This important initial
decision was made based on the fact that the four classes are, in
some sense, arbitrarily defined as specific thresholds for the
MMSE and NFT scores that were decided ad hoc. Therefore, we
decided to first focus on the transitional patterns that can be
identified from a ‘‘normally aging’’ to an ‘‘AD-severe’’ gene
expression profile in hippocampus. With this approach, we also
avoid selecting genes that diverge from the normal-aged profile by
causes other than AD, as we expect that the severity scale in AD
has a higher probability of being correct in the ‘‘Severe AD’’ cases
(since they have high values of NFT and low MMSE scores, clearly
a joint combination highly appreciated as a disease hallmark). This
approach has an additional advantage. Using this particular
dataset and with focus on the effects of incorrect diagnoses, two
publications indentify four possible misdiagnoses between control
and incipient AD [9,10]. In our case, the samples that have been
labelled either ‘‘Incipient AD’’ or ‘‘Moderate AD’’ play the role of
a ‘‘Test set’’, as they are not used to select probes for establishing a
molecular signature, thus avoiding misdiagnoses problems.
Results
The results have been obtained using four steps in tandem: 1)
abundance quantization of gene expression values and filtering of
probes (this step is supervised by using the samples labelled either
‘‘Control’’ or ‘‘Severe AD’’); 2) a feature selection algorithm to
refine the probe selection based on numerical solution of a
combinatorial optimization problem (the (alpha,beta)-k-Feature Set
methodology); 3) a correlation analysis (that requires the
computation of Jensen-Shannon divergences). Finally, a fourth
step involves the pathway and Gene Ontology analysis of the
results.
The first two steps only used the samples labelled either
‘‘Control’’ or ‘‘Severe AD’’. The third step requires several
procedures and uses all of the samples. We first compute an
Figure 4. Correlation of the expression profiles of 1,372 probes (across samples) with the sqrtJSD of the samples of two reference
groups (‘‘Control’’ and ‘‘Severe AD’’, represented by the average expression profile in the group). The 50 probes in red are those most
distant from the origin of this system of coordinates. Those probes have expression-value variations that are correlated with the divergences of the
average ‘‘Control’’ profile and at the same time with the ‘‘Severe AD’’.
doi:10.1371/journal.pone.0010153.g004
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Jensen-Shannon divergence with the average Control gene
expression profile.
Gene symbol Probe Spearman rank correlation
1 CSF1 211839_s_at 0.79388
2 MCL1 214057_at 0.75484
3 PSMC3IP 205956_x_at 0.74816
4 ZHX3 217367_s_at 0.74416
5 C10orf76 55662_at 0.74093
6 FCAR 211307_s_at 0.72002
7 TUBD1 210389_x_at 0.71835
8 AW974666 222365_at 0.71835
9 LRP10 201412_at 0.71079
10 SERTAD2 202656_s_at 0.70679
11 ITGB5 201125_s_at 0.7059
12 CDC2L6 212899_at 0.70412
13 RNF19A 220483_s_at 0.70367
14 TTN 208195_at 0.70278
15 DHFR 202534_x_at 0.69844
16 FYCO1 218204_s_at 0.69655
17 HBEGF 38037_at 0.69388
18 ZBTB20 205383_s_at 0.69121
19 KCNK5 219615_s_at 0.69121
20 KLHL20 204177_s_at 0.68988
21 DLG5 201681_s_at 0.68899
22 CHD2 203461_at 0.68821
23 TUG1 222244_s_at 0.68721
24 ZNF500 213641_at 0.68454
25 N58524 222332_at 0.68276
26 KIR2DL5A 211410_x_at 0.68165
27 CYBRD1 217889_s_at 0.67964
28 DLG1 217208_s_at 0.67831
29 IL15 205992_s_at 0.67731
30 RND2 214393_at 0.67508
31 TNS1 221748_s_at 0.67253
32 CTBP2 210835_s_at 0.6703
33 AL050204 213929_at 0.66852
34 YES1 202933_s_at 0.66763
35 MYBL1 213906_at 0.66719
36 No gene associated 213256_at 0.66363
37 C5orf4 48031_r_at 0.66363
38 FOXO1 202724_s_at 0.66318
39 UPF1 211168_s_at 0.66096
40 STAG3L1 221191_at 0.66007
41 SLC12A7 218066_at 0.65784
42 CYP3A4 205999_x_at 0.65695
43 KRCC1 218303_x_at 0.65562
44 P53AIP1 220402_at 0.65462
45 TLE3 212769_at 0.6535
46 ZNF669 220215_at 0.65206
47 CFLAR 214486_x_at 0.65206
48 PAK4 203154_s_at 0.65028
Gene symbol Probe Spearman rank correlation
49 M78162 217536_x_at 0.6485
50 MMP11 203876_s_at 0.6485
51 RGS7 206290_s_at 20.67475
52 ASTN1 213197_at 20.67653
53 TMSB10 217733_s_at 20.67653
54 SUPT4H1 201484_at 20.67731
55 COX6B1 201441_at 20.67742
56 WASF1 204165_at 20.67742
57 RALYL 213967_at 20.67786
58 BBS7 219688_at 20.67875
59 SEC31A 200945_s_at 20.68009
60 DDX1 201241_at 20.68009
61 RP11-336K24.9 218291_at 20.68098
62 GABBR2 209990_s_at 20.68231
63 SLC25A12 203340_s_at 20.68454
64 ATP5C1 205711_x_at 20.68587
65 NEFL 221805_at 20.68632
66 NDUFB8 201226_at 20.68854
67 OPA1 212214_at 20.69255
68 KPNA2 201088_at 20.69522
69 PPIA 211765_x_at 20.69566
70 CYP26B1 219825_at 20.69566
71 COX7AP2 217249_x_at 20.69878
72 VSNL1 203798_s_at 20.69878
73 ATP6V1D 208898_at 20.70145
74 ATP5C1 213366_x_at 20.70234
75 NRXN1 209915_s_at 20.7059
76 PCSK2 204870_s_at 20.70901
77 AI708767 211978_x_at 20.71034
78 UGCGL2 218801_at 20.71257
79 KIAA0528 212943_at 20.7139
80 SERPINI1 205352_at 20.71657
81 LZTS1 219042_at 20.71835
82 NEFM 205113_at 20.71835
83 FRY 204072_s_at 20.71924
84 CSPG5 205344_at 20.72291
85 COX6A1 200925_at 20.7277
86 COX4I1 202698_x_at 20.73037
87 KIAA0368 212428_at 20.73126
88 MYT1L 210016_at 20.73304
89 PPP3CA 202457_s_at 20.74194
90 LOC100131599 213222_at 20.74549
91 CACNG3 206384_at 20.75484
92 PPP3R1 204506_at 20.75573
93 MAN1A1 221760_at 20.75929
94 NETO2 218888_s_at 20.76819
95 LPHN1 219145_at 20.76852
96 CAPRIN2 218456_at 20.76997
97 CAMK1G 215161_at 20.77041
98 LDB2 206481_s_at 20.7802
Table 1. Cont.
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‘‘Severe AD’’. This step is followed by the computation of the
square root of the Jensen-Shannon divergence [11] of the gene expression
profile of each sample with the average profiles of the classes
‘‘Control’’ and ‘‘Severe AD’’. Finally, we perform a correlation
analysis of each gene expression profile (now across all samples)
with the results of the square root of the Jensen-Shannon
divergence (we do it twice, one for the ‘‘Control’’ and the other
for the ‘‘Severe AD’’ case). With this information, and using state-
of-the-art pathway analysis and text mining tools, as a result of our
final analysis step, we provide a comprehensive list of results of the
differentially regulated genes, patterns of up (down)-regulation and
the pathways that seem to be implicated in the progression of AD.
We refer to the Methods section for a completely reproducible and
in-depth explanation of our methodology.
Probe selection and Jensen-Shannon divergence
computations based on class information
We start our analysis with a baseline comparison, which we
have chosen to include for illustrative purposes. Figure 1 provides
an example of the importance of performing an initial probe/gene
selection step. The example serves as an argument for the necessity
of the first two steps of our method. We have normalized each
individual gene expression profile, and we have computed the
average gene expression profile for classes ‘‘Control’’ and ‘‘Severe
AD’’ (following the same procedure we will use in the third step of
our method, but in this case using all probes in the array).
We have used the square root of the Jensen-Shannon
divergence of a pair of samples (a pair of gene expression profiles)
as our measure of ‘‘dissimilarity’’ between them. The square root
of the Jensen-Shannon divergence quantifies the difference
between two probability distribution functions (PDFs) and it is a
metric (we refer the reader to the Methods section for a
mathematical definition and a discussion of its properties).
Figure 1 plots the divergence of each sample with the average
expression profile of the classes ‘Control’ and ‘Severe AD’;
sqrtJSD(P,  P PC) denotes the square root of the Jensen-Shannon
divergence between sample P and the average profile on the
‘Control’ class ( P PC). Analogously, sqrtJSD(P , P PS) denotes the
square root of the Jensen-Shannon divergence between sample P
and the average profile on the ‘Severe AD’ class ( P PS). The
advantage of using the probe/gene selection steps, which reduces
the number of genes to the most informative ones, will be evident
when we later compare Figure 1 with Figure 2. However, Figure 1
already shows some interesting patterns. For instance, we can
observe that a high percentage of the samples from AD patients
(having either ‘Incipient AD’, ‘Moderate’ or ‘Severe’ labels) show
sqrtJSD(P,  P PC) values greater than 0.115, which indicates
measurable divergence with the Control average gene expression
profile.
Figure 2 presents the same procedure, but only after the feature
selection step has significantly reduced the number of probes fom
22,215 to 1,372. We refer to the Methods section for details. In
Figure 2, an arguably more coherent arrangement can be
observed. As expected, the group of control samples (in green)
have lower values of sqrtJSD(P,  P PC) and higher values of sqrtJSD
(P,  P PS). Obviously, the opposite behaviour is observed for the
samples belonging to the severe cases. What cannot be expected,
however, is a layout of the samples that could provide evidence of
a continuous ‘‘progression’’ of the disease. The Figure shows that
the samples of ‘Incipient AD’ are close to the control group and
the ‘Moderate AD’ samples are closer to them and also link to
severe AD. A priori, since those samples had not been used for
probe selection, they could have been in any position in the
(sqrtJSD(P , P PC), sqrtJSD(P,  P PS) plane.
Finally, Figure 3 presents the results of the MMSE score as a
function of the sqrtJSD(P ,  P PC), showing an inverse correlation
between them. A similar situation happens between MMSE and
sqrtJSD(P, P PS), but in this case low MMSE scores correspond to
low values of sqrtJSD(P,Ps), giving a positive correlation. It is this
interplay between positive and negative correlations that has
enabled us to find interesting biomarkers. In the next subsection,
we explain how these correlations were used to identify probes that
‘‘diverge from’’ their values in the ‘‘Control’’ group and ‘‘converge
to’’ the values in the ‘‘Severe AD’’ group.
Gene correlation analysis
The third step employs a correlation analysis to select the group
of probes that are the most strongly correlated. Intuitively, the idea
is fairly straightforward as illustrated in the following ‘‘Gedank-
enexperiment’’ (a thought experiment). Assume, for argument’s
sake, that the MMSE of each patient P is not actually phenotypical
information assigned to each sample. Instead, assume that the
MMSE values are the microarray probe expression of some gene.
In this ‘‘thought experiment’’, let MMSE(P) be the expression of
this hypothetical gene probe on sample P, and fDataset be the set of
values it has for each sample. The correlation of the sample-
ordered set of values {MMSE(P)} with the set of sample-ordered
values {sqrtJSD(P,  P PC)} is negative, indicating that, in general, this
hypothetical MMSE probe reduces its values as the whole gene
expression profile of sample P diverges from the average
‘‘Control’’ profile (Figure 3). Analogously, there exists a positive
correlation of the set of values {MMSE(P)} with the values of the
set {sqrtJSD(P, P PS)}. This indicates that the values of MMSE tend
to be reduced as the profile of sample P ‘‘converges to’’ the average
profile of samples in the ‘‘Severe AD’’ group. We have computed
these correlations for all probes in the signature, which are given in
the supplementary material (File S2 sheet ‘correlation Analysis’)
and are the basis for our analysis.
We also refer the reader to Figure 4, which presents the
computed correlations. Tables 1 and 2 present the one hundred
most correlated probes (in absolute values). In the supplementary
material (File S2 sheet ‘correlation Analysis’), the correlation of
each of the 1,372 probes that were selected by our method is given
(and annotated, including Affymetrix and Stanford’s Source
outputs) to facilitate further analyses.
As the objective is to detect the probes correlated with the
progression of AD, we will select those probes with high absolute
correlations values with both groups, an indication of a
Gene symbol Probe Spearman rank correlation
99 TRIM36 219736_at 20.79622
100 LDHA 200650_s_at 20.80245
These values are then correlated with the individual expression profiles of each
probe across the set of samples samples. We list here the 100 probes that have
the highest Spearman correlation (absolute value, computed over all samples)
between the expression of the probe and the square root of the Jensen-
Shannon divergence of the sample with the average Control gene expression
profile. Rows in boldface indicate the cases for which a putative relationship
exist in the published literature between the gene and AD. A probe that has a
positive correlation with the square root of the Jensen-Shannon divergence
with the average Control gene expression profile roughly indicates, in this case,
a probe that, over all samples in the set, tends to increase its expression from
their values in the ‘‘Control’’ group to the ‘‘Severe AD’’.
doi:10.1371/journal.pone.0010153.t001
Table 1. Cont.
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correlation (absolute value, computed over all samples)
between the expression of the probe and the square root of
the Jensen-Shannon divergence of all samples with the
average Severe AD gene expression profile.
Gene symbol Probe Spearman rank correlation
1 NEFM 205113_at 0.84472
2 NRG1 206343_s_at 0.83003
3 VSNL1 203798_s_at 0.80156
4 NEFL 221805_at 0.79889
5 SLC25A12 203340_s_at 0.79666
6 BCL11A 219497_s_at 0.79266
7 RALYL 213967_at 0.78776
8 SERPINI1 205352_at 0.78242
9 ATP2B2 204685_s_at 0.78154
10 LDB2 206481_s_at 0.7802
11 ENSA 202596_at 0.77931
12 NDUFV2 202941_at 0.77753
13 KIAA0319 206017_at 0.76418
14 ATP5C1 213366_x_at 0.7584
15 TAGLN3 204743_at 0.75617
16 SV2B 205551_at 0.75484
17 DOPEY1 213271_s_at 0.75439
18 FAR2 220615_s_at 0.75395
19 SNRK 209481_at 0.7535
20 TRIM36 219736_at 0.74994
21 NRXN1 209915_s_at 0.74772
22 PKP4 214874_at 0.74461
23 CALM3 200622_x_at 0.74149
24 PIP4K2C 218942_at 0.73971
25 CRYM 205489_at 0.73437
26 SCFD1 215548_s_at 0.73037
27 COX6A1 200925_at 0.72992
28 OPA1 212214_at 0.7277
29 ATP5C1 205711_x_at 0.72414
30 LETMD1 207170_s_at 0.71969
31 PPP2R2B 213849_s_at 0.71657
32 UQCRQ 201568_at 0.71301
33 FKBP3 218003_s_at 0.71268
34 PBX1 212148_at 0.71123
35 CACNG3 206384_at 0.71079
36 TMSB10 217733_s_at 0.70812
37 KIAA1467 213234_at 0.70812
38 INA 204465_s_at 0.7059
39 ARF5 201526_at 0.70545
40 CD200 209582_s_at 0.70456
41 CAMK1G 215161_at 0.70367
42 TUBG2 203894_at 0.70234
43 LDHA 200650_s_at 0.70189
44 LOC100131599 213222_at 0.70056
45 DIMT1L 210802_s_at 0.697
46 RGS4 204339_s_at 0.69655
Gene symbol Probe Spearman rank correlation
47 CAMKK2 212252_at 0.69611
48 BE731738 212661_x_at 0.69477
49 PPP2CA 208652_at 0.69388
50 SRD5A1 211056_s_at 0.69388
51 DMN 212730_at 20.68409
52 AW974666 222365_at 20.68721
53 SLC33A1 203164_at 20.68899
54 SYNC1 221276_s_at 20.68954
55 ITGB5 201125_s_at 20.69299
56 CNOT6 217970_s_at 20.69655
57 DYNLT1 201999_s_at 20.697
58 ZMYND8 214795_at 20.697
59 TBL1X 213400_s_at 20.69967
60 RND2 214393_a 20.70378
61 LRP10 201412_at 20.70545
62 GMPR 204187_at 20.70768
63 LTF 202018_s_at 20.70812
64 CSNK1A1 208865_at 20.70812
65 NBPF12 213612_x_at 20.70901
66 ZFP36L2 201368_at 20.70945
67 AV712577 201305_x_at 20.71212
68 FDFT1 208647_at 20.71257
69 ADARB2 220648_at 20.71301
70 CPT2 204264_at 20.7139
71 ADD3 201753_s_at 20.71524
72 37681 213256_at 20.71613
73 ITGB8 205816_at 20.71924
74 RBM19 205115_s_at 20.71969
75 HIST1H1C 209398_at 20.72058
76 NM_018612 220882_at 20.73037
77 CD68 203507_at 20.73259
78 GTF2A1L 213413_at 20.73348
79 FAM114A1 213455_at 20.73571
80 FOXO1 202724_s_at 20.73749
81 C6orf145 212923_s_at 20.73882
82 KRCC1 218303_x_at 20.74149
83 TGFBR3 204731_at 20.74372
84 ZHX3 217367_s_at 20.74594
85 TSPO 202096_s_at 20.74816
86 STAT5A 203010_at 20.74994
87 AFF1 201924_at 20.75039
88 RASL12 219167_at 20.75217
89 AL359052 214927_at 20.75528
90 ALDH3A2 202054_s_at 20.75706
91 C1S 208747_s_at 20.76062
92 AV700298 217523_at 20.76062
93 HBEGF 38037_at 20.76819
94 BG251521 213156_at 20.77086
95 ZBTB20 205383_s_at 20.77353
96 AL049443 215306_at 20.78109
Table 2. Cont.
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convergence to the severe AD profile; these correlations
computed over all sample types. We need to check both groups
according to their correlations to the average profile. The first
group of probes we are interested in are those that have a positive
correlation with the sqrtJSD(P, P PC) and a negative correlation with
sqrtJSD(P, P PS). The probes in this group are those probes with
under-expression in the non-disease sample but are over-
expressed in the severe AD cases. The second group has the
opposite behaviour, the probes’ expression values have a negative
correlation with sqrtJSD(P, P PC) and a positive correlation with
sqrtJSD(P, P PS). This pattern can be visualised in Figure 4, where
the elliptical shape of the dispersion of the probes in this scatter
plot indicates that our methodology has preserved all the
significant probes for both classes and that there are no probes
(after the filter) presenting a high correlation simultaneously with
the control and severe AD profiles.
On these values a new selection criterion is applied, as we
wanted to identify the group of probes that have strong
correlations to both groups in absolute value. This symmetry
of our argument stems from the interest in understanding the
biology of the progression of the disease. For identifying disease
biomarkers we may just concentrate in finding the probes that
present an upregulation trend when progressing from ‘‘Control’’
to ‘‘Disease’’. However, here we w o u l da l s ol i k et oi d e n t i f yt h o s e
probes that become increasingly downregulated, which, in turn,
w o u l dh e l pu st oi d e n t i f ys i g n i f i cantly dysregulated biological
pathways (as members of the pathway will be either up or
downregulated). Towards this end, we rank the probes in the
order given by their Euclidean distance from the origin of
coordinates in Figure 4. We selected an arbitrary cut-off value of
fifty probes (the selected probes are marked in red). These fifty
probes are also identified by their Gene Symbols in Figures 5
and 6.
Calculating the distance of each probe to the origin, on the
sqrtJSD system of coordinates, we further selected the 50 most
distant probes and analysed their behaviour. Table 3 presents the
50 probes (corresponding to 48 genes), their correlation to each
group and their distance to the origin of coordinates. File S2 sheet
‘correlation Analysis’ column ‘E - Distance’ of the supplementary
Gene symbol Probe Spearman rank correlation
97 PTTG1IP 200677_at 20.78154
98 FYCO1 218204_s_at 20.78598
99 ATP6V0E1 214150_x_at 20.802
100 SERTAD2 202656_s_at 20.84338
We listed the top fifty probes with positive and negative correlation. Rows in
boldface indicate the cases for which a putative relationship exist in the
published literature between the gene and AD. A probe that has a positive
correlation with the square root of the Jensen-Shannon divergence with the
average Control gene expression profile roughly indicates a probe that, over all
samples in the set, tends to increase its expression from their values in the
‘‘Control’’ group to the ‘‘Severe AD’’.
doi:10.1371/journal.pone.0010153.t002
Table 2. Cont.
Figure 5. Zoom of Figure 4, identifying the most distant probes from the origin with negative correlation with the control profile,
d sqrtJSD P,PC ðÞ ðÞ and positive correlation with the severe profile, d sqrtJSD P,PS ðÞ ðÞ .
doi:10.1371/journal.pone.0010153.g005
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analysed. In Table 3, it can be seen which genes have some
putative annotation that links them to AD (17 genes out of 48).
Figure 7 shows the heat map of the 50-probe signature, where
the probes and patient samples are ordered by considering the
similarity of their gene-expression values only. It can be observed
that the Memetic Algorithm (MA), a high performance combina-
torial optimization ordering method [12] for microarray datasets
introduced in 2007, ordered most of the patients with or without
an incipient level of AD on the left and the more severe cases on
the right. When ordering the probes’ gene expression, the MA
perfectly sorted the groups previously described. We refer to
[12,13] for details of the MA. The supplementary material (File S2
‘1372 norm. +heat map+GO’) presents the heat map of the 1,372
gene-probes, with samples and probes sorted by the MA.
Transcription factors analysis of most correlated probes
The signature of 50 probes we present in Figure 7 has 48
different genes (some probes are related to the same gene). The
two repeated genes in this 50-probe list are ATP5C1 (ATP
synthase, H+ transporting, mitochondrial F1 complex, gamma
polypeptide 1) and PPIA (peptidylprolyl isomerase A (cyclophilin
A)) [14,15,16,17], a calcineurin regulatory protein. A recent study
that used RT-PCR to examine tissue from 90 AD and 81 control
human brains reports that cyclophilin is reduced in AD (both for
females and males as compared with their gender-matched groups)
[18]. We note here that the cutoff of 50 probes circumscribes the
initial description a little, but most of the later discussion uses
information from the whole signature to identify dysregulated
pathways. Figure 8 presents the heat map of the 1,372-probe
signature. The probes were sorted with the MA but the samples
remain in the same position as obtained previously with the 50-
probe signature.
We analysed this list of genes using GATHER [19], an online
tool for annotating signatures. Forty-one genes out of fifty have a
motif for EVI1 (ecotropic viral integration site 1) and thirty-nine of
them have a binding motif with V$TCF1P_Q6 (TCF1: transcrip-
tion factor 1, hepatic; LF-B1, hepatic nuclear factor (HNF1),
albumin proximal factor). The same analysis can be done if we
divide the set of genes in two groups. The first group has positive
correlation with the control profile and are overexpressed in AD;
the second group has a positive correlation with the severe profile,
and tend towards being underexpressed in AD (see Table 3).
Table 4 presents the overrepresented motifs. We note, however,
that we believe that the best results to identify putative
overrepresented regulatory motifs can be obtained using the
whole signature of 1,372 probes, and we will present the results of
this investigation after presenting the case of the most correlated
probes.
Another interesting pattern emerged when analysing the
KEGG Pathways of the 50-probe signature using GATHER
and PATHWAY Studio [20]. Using GATHER, three KEGG
Pathways appear significantly represented, Amyotrophic lateral
sclerosis (ALS), Oxidative phosphorylation and ATP synthesis.
Using PATHWAY Studio, we automatically built the ‘‘common-
regulators’’ diagram by selecting a filter that only considers protein
interactions and binding. The resulting diagram is presented in
Figure 9. As can be seen from the figure, we have chosen a circular
Figure 6. Zoom of Figure 4, identifying the most distant probes from the origin with positive correlation with the control profile,
d sqrtJSD P,PC ðÞ ðÞ and negative correlation with the severe profile, d sqrtJSD P,PS ðÞ ðÞ .
doi:10.1371/journal.pone.0010153.g006
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Probe Set ID Gene Symbol Gene Title d(sqrtJSD (P,Pc)) d(sqrtJSD (P,Ps)) Dist O Ref (ADG)
206481_s_at LDB2 LIM domain binding 2 20.7988 0.7427 1.0907
219736_at TRIM36 tripartite motif-containing 36 20.8077 0.7242 1.0848
200650_s_at LDHA lactate dehydrogenase A 20.8210 0.6984 1.0778
205113_at NEFM neurofilament, medium polypeptide
150kDa
20.7448 0.7742 1.0743 [379,649,672,673,674,
675,676,677,678,679,
680,681,682,683,684,
685,686,687,688,689,
690,691,692,693,694,
695,696,697,698,699,
700,701,702]
202656_s_at SERTAD2 SERTA domain containing 2 0.7343 20.7827 1.0732
203798_s_at VSNL1 visinin-like 1 20.7093 0.7923 1.0634 [565,566,638,641,
642,703,704,705]
205352_at SERPINI1 serpin peptidase inhibitor, clade I
(neuroserpin), member 1
20.7432 0.7496 1.0555 [706,707,708,709,
710,711,712,713,714]
217367_s_at ZHX3 zinc fingers and homeoboxes 3 0.7677 20.7129 1.0477
209915_s_at NRXN1 neurexin 1 20.7282 0.7496 1.0451
221805_at NEFL neurofilament, light polypeptide 68kDa 20.7153 0.7552 1.0402 [715,716,717]
213366_x_at ATP5C1 ATP synthase, H+ transporting, mitochondrial
F1 complex, gamma polypeptide 1
20.7302 0.7327 1.0344
203340_s_at SLC25A12 solute carrier family 25 (mitochondrial carrier,
Aralar), member 12
20.7141 0.7444 1.0315 [718]
213967_at RALYL RALY RNA binding protein-like 20.6786 0.7758 1.0307
215161_at CAMK1G calcium/calmodulin-dependent protein
kinase IG
20.7819 0.6682 1.0285
218204_s_at FYCO1 FYVE and coiled-coil domain containing 1 0.7250 20.7222 1.0233
213222_at PLCB1 phospholipase C, beta 1
(phosphoinositide-specific)
20.7694 0.6738 1.0227 [719,720,721,722,
723,724]
200925_at COX6A1 cytochrome c oxidase subunit VIa
polypeptide 1
20.7532 0.6883 1.0204
38037_at HBEGF heparin-binding EGF-like growth factor 0.7222 20.7194 1.0193 [725]
209481_at SNRK SNF related kinase 20.7048 0.7331 1.0169
201412_at LRP10 low density lipoprotein receptor-related
protein 10
0.6964 20.7399 1.0161
202941_at NDUFV2 NADH dehydrogenase (ubiquinone)
flavoprotein 2, 24kDa
20.6984 0.7379 1.0160
205383_s_at ZBTB20 zinc finger and BTB domain containing 20 0.6774 20.7569 1.0157 [726,727]
206384_at CACNG3 calcium channel, voltage-dependent,
gamma subunit 3
20.7778 0.6516 1.0147
218888_s_at NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 20.7899 0.6246 1.0070
212214_at OPA1 optic atrophy 1 (autosomal dominant) 20.7194 0.7024 1.0054 [728,729,730,731,732,
733,734,735,736,737,
738,739,740,741,742]
218456_at CAPRIN2 caprin family member 2 20.7915 0.6186 1.0046
211307_s_at FCAR Fc fragment of IgA, receptor for 0.7297 20.6886 1.0033
202724_s_at FOXO1 forkhead box O1 0.6875 20.7270 1.0006 [743,744,745]
219145_at LPHN1 latrophilin 1 20.7293 0.6826 0.9989 [746]
205711_x_at ATP5C1 ATP synthase, H+ transporting, mitochondrial
F1 complex, gamma polypeptide 1
20.7153 0.6968 0.9986
55662_at C10orf76 chromosome 10 open reading frame 76 0.7632 20.6420 0.9973
211978_x_at PPIA peptidylprolyl isomerase A (cyclophilin A) 20.7363 0.6726 0.9972 [747,748,749,750]
210016_at MYT1L myelin transcription factor 1-like ///
hypothetical protein LOC100134306
20.7577 0.6395 0.9915
204072_s_at FRY furry homolog (Drosophila) 20.7456 0.6512 0.9899
219497_s_at BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 20.6843 0.7117 0.9873
201125_s_at ITGB5 integrin, beta 5 0.7323 20.6613 0.9867
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signature [1] (IL1-a, TNF-a, IL-3, EGF and G-CSF) in plasma
(plus IL-6) appears to have a strong relationship with CSF1 (colony
stimulating factor 1 (macrophage)), the most positive correlated
gene with the control profile (see Table 1). It is also worth
mentioning, that CSF1 was found differentially expressed in blood
of AD and Control subjects and belongs to the 18-protein
signature uncovered by Ray et al. [2] in 2007.
Five of the 50 most correlated probes correspond to
genes already mapped to KEGGs Alzheimer’s disease
Pathway KEGG:05010 and together with LDHA they link
to impaired metabolism and the ‘‘novel glucocorticoid
hypothesis’’
We have observed that five genes, which are the most correlated
probes with our putative signature for disease severity, can be
mapped to the AD pathway of the Kyoto Encyclopaedia of Genes
KEGG:05010. They are ATP5C1, COX6A1 [21,22], NDUFV2
[23,24,25,26,27,28,29,30], PLCB1[31,32,33,34], and PPP3CA
(protein phosphatase 3 (formerly 2B), catalytic subunit, alpha
isoform), the last one also known as Calmodulin-dependent
calcineurin A subunit alpha isoform. In all cases, the probes
showed a reduction of expression with AD severity, which may
indicate a sign of impaired mitochondrial functions and energy
uptake [35,36].
In addition to these five, we observed the reduced expression of
the glycolytic enzyme LDHA, which may also indicate another
challenge for energy metabolism in these neurons. Although
glucose is generally considered to be the only substrate for brain
energy metabolism, moncarboxylates have also been hypotheised
as alternative substrates [37]. Laughton et al. report segregation in
the hippocampus, with LDHA present in astrocytes and not in
neurons. Instead, it is pyruvate dehydrogenase that is present in
neurons but not in astrocytes and as a consequence of this study
they support the argument that a metabolic compartmentalization
exists in the human cortex and hippocampus where lactate
produced by astrocytes could be oxidized by neurons [37]. We
have also observed a reduction in expression of a probe that
corresponds to PDHA1 (Pyruvate dehydrogenase (lipoamide)
alpha 1, 200980_s_at) with increasing AD severity. The reduction
of PDH expression, and the concurrent increase in pyruvate
carboxylase gene expression, was discussed by Landfield et al. [38],
who argue that: ‘‘These changes suggest that reduced pyruvate flux through
PDH and decreased oxidative metabolism of glucose may develop early in AD.
Interestingly, the inactivation of PDH is also a major pathway through which
glucocorticoid activity acts to conserve glucose, and apparently, to induce insulin
resistance [65,66]. Thus, our data are consistent with the possibility that GC
effects on this and other important target pathways in brain are enhanced in
both aging and AD. If so, such alterations in glucocorticoid efficacy may have
implications for AD pathogenesis as well as for the increased risk of AD
associated with normal aging.’’ Our results seem to indicate that
LDHA might also be discussed within the extended metabolic
pathways that serve as the basic framework of this novel, more
complex hypothesis [38,39,40,41,42,43,44,45,46,47,48,49,50,51,
52,53,54,55].
Four of the 50 most correlated gene probes are linked to
synaptic function and neurofilament bundle assembly
and also have reduced expressions with AD severity
NEFM, NRXN1, SV2B, and NEFL all have a similar pattern
of reduced gene expression with AD severity. Experiments with
mice depleted of the NEFL have been previously reported in the
Probe Set ID Gene Symbol Gene Title d(sqrtJSD (P,Pc)) d(sqrtJSD (P,Ps)) Dist O Ref (ADG)
211765_x_at PPIA peptidylprolyl isomerase A (cyclophilin A) 20.7230 0.6714 0.9866 [747,748,749,750]
214057_at MCL1 Myeloid cell leukemia sequence 1 (BCL2-related) 0.7722 20.6137 0.9864 [751]
211839_s_at CSF1 colony stimulating factor 1 (macrophage) 0.8120 20.5590 0.9858 [752,753,754,755,756,
757,758,759,760,761,
762,763,764,765,766,
767,768,769,770,771,
772,773,774,775,776,
777,778,779,780,781,
782]
205551_at SV2B synaptic vesicle glycoprotein 2B 20.6915 0.7008 0.9846 [66]
219167_at RASL12 RAS-like, family 12 0.6226 20.7605 0.9828
214393_at RND2 Rho family GTPase 2 0.7051 20.6799 0.9796
212899_at CDC2L6 cell division cycle 2-like 6 (CDK8-like) 0.7319 20.6504 0.9791
220615_s_at MLSTD1 male sterility domain containing 1 20.6665 0.7149 0.9774
201681_s_at DLG5 discs, large homolog 5 (Drosophila) 0.7093 20.6706 0.9761
208195_at TTN titin 0.7173 20.6617 0.9759 [783]
202457_s_at PPP3CA protein phosphatase 3 (formerly 2B), catalytic
subunit, alpha isoform
20.7661 0.6016 0.9741
214150_x_at ATP6V0E1 ATPase, H+ transporting, lysosomal 9kDa, V0
subunit e1
0.6230 20.7488 0.9741
204743_at TAGLN3 transgelin 3 20.6952 0.6802 0.9726
213197_at ASTN1 astrotactin 1 20.7069 0.6673 0.9721
The column ‘‘Dist O’’ shows the Euclidean distance from the origin for each gene. If the gene has a known relation with AD (ADG), the reference’s codes are display in
column ‘‘Ref ADG’’.
doi:10.1371/journal.pone.0010153.t003
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NFL mRNA levels seen in amyotrophic lateral sclerosis and causes perikaryal
accumulation of neurofilament proteins and axonal hypotrophy in motoneurons.
NFL2/2 mice was evaluated for regional brain metabolism by means of
quantitative histochemical estimation of cytochrome oxidase activity.’’ [56].
Mutations in the NEFL gene [56,57,58,59,60,61,62] and in the
NEFM [63] have been linked to Charcot-Marie-Tooth disease.
We will discuss the loss of expression of NRXN1 (Neurexin 1)
later, when we comment on its presence in a panel of putative
genes linked to prion-induced neurodegeneration [64]. However,
we note here that both NRXN1 and NEFL appeared to be
downregulated on a transcriptional profiling study of prion
infection in mice [65].
The loss of expression of SV2B is also interesting. In 2001,
Heese et al. [66] reported ‘‘a new transcript of SV2B (SV2Bb) mRNA
that is up-regulated at mRNA level in neurons by amyloid beta peptide (Abeta)
fragment (1–42). In comparison to SV2B this new mRNA encodes for the
same protein but it has an elongated 39-untranslated region (39UTR) that
contains several AU-rich (AUR) cis-acting elements which are probably
involved in posttranscriptional regulating of SV2Bb translation. In conclusion,
alteration of SV2B(b) expression appears to be involved in processes of neuronal
degeneration’’ (see also [67]). We note that SV2B is only expressed in
vesicles that undergo calcium-regulated exocytosis [68] and is a
regulator of synaptotagmin 1 [69], which is a synaptic calcium
sensor with a role in neurotransmitter release previously studied in
AD [70,71,72,73,74,75]. We present a number of genes related to
synaptic function and neuronal plasticity which are increasingly
down/up regulated later on the manuscript and on the
supplementary material (File S3 Sheet ‘Synapse’).
Analysis of the 1,372-probe signature reveals alterations
in calcium and insulin signalling
Using GATHER, we have identified 32 genes in the Calcium
signalling pathway http://www.genome.jp/dbget-bin/show_pathway?
hsa04020 (p-value,0.009). They are ADCY2, ADORA2B, AGTR1,
ATP2A3, ATP2B1, ATP2B2, ATP2B4, AVPR1A,C A L M 1 ,
CALM3, CREBBP, GNA14, GNAS, GRM5, HTR2A,I T P R 1 ,
ITPR2, LHCGR, NFATC1,P H K A 2 ,PLCB1,P L C E 1 ,PPP3CA,
PPP3R1, PRKCB1, PTAFR, SLC25A6, SLC8A2, SYK, TBXA2R,
TNNC2, and TTN. We cannot do enough justice in this manuscript to
the several different hypotheses that point at imbalances/deregulation
in calcium signalling and AD pathology. Instead,we contribute to these
interesting discussions with our findings of genes related to this pathway
within this group of 32 genes. The gene symbols in boldface can be
mapped to the KEGG Pathway hsa04080, Neuroactive ligand-receptor
interaction; those in italics can be mapped to KEGG Pathway hsa04310,
Wnt Signalling. Being aware of the existing interest on Wnt Signalling
and AD, we went back to the list of genes present in our (alpha,beta)-k-
feature set signature and we identified others that can also be linked to
Wnt signalling, like CSNK1G3, CSNK2A2, FRAT1[76,77,78,79,
Figure 7. Heat map of the 50-probe signature and the transcription factors with best p-values, for the whole set of 50 probes and
for the two groups considered. The samples and probes were sorted using the memetic algorithm given in [12], using the Euclidean distance.
The transcription factors were obtained using Chang and Nevins’ GATHER system to interpret genomic signatures [634]. The coloured cell and the
number 1 indicate that the transcription factor has a binding motif with the gene for that row. The levels of severity as defined by Blalock et al. [635]
are indicated in the first line: (0) Control, (1) Incipient AD, (2) Moderate AD and (3) Severe AD.
doi:10.1371/journal.pone.0010153.g007
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SOX2 [92,93,94,95,96], TCF7L1/TCF3[89,97,98], TCF7L2/TCF4
[99,100,101,102,103,104,105,106], and TLE3[106,107,108,109].
In addition, most of the remaining 32 genes in the Calcium
signalling pathway can be mapped to KEGG Pathway hsa04070,
Phosphatidylinositol signalling system (CALM1, CALM3, ITPR1,
ITPR2, PLCB1, PLCE1, PRKCB1), and Gap Junction (ADCY2,
GNA14, GNAS, GRM5, HTR2A, ITPR1, ITPR2, PLCB1,
PRKCB1).
This fact suggested that we should check how many genes were
mapped to these pathways. We found that Phosphatidylinositol
signalling system was indeed the third pathway with most ‘‘hits’’ in
our signature, and also with other 12 genes (CDIPT, CSNK1G3
PIK3C3, PIK3R1, PIK3R4, PI4KB, PIP5K1A, PIP5K1C,
PIP4K2C, PTEN, SKIP and TTK) which brings the total number
to 19. We have also found (CCND3, CSNK1A1, CSNK2A2,
CTBP1, CTBP2, FRAT1, FZD5, PPARD, PPP2CA, PPP2R2B,
RBX1, SMAD3, TBL1X, TCF7L1, TCF7L2, VANGL1) bringing
the total to 22 genes. We refer the reader to the supplementary
material (File S3 Sheet ‘Phosphatidylinositol signalling’) for
inspection of the individual pattern of expression of all these genes.
Together with the 20 genes mapped to the Insulin signalling
pathway KEGG hsa04910 (ACACA, CALM1, CALM3, EIF4E2,
FOXO1A, INSR [110,111,112,113,114,115,116,117], MAPK1,
PDE3A, PHKA2, PIK3R1, PIK3R4, PPP1CC, PRKAR2A,
PRKAR2B, PRKCI, RHEB, RHOQ, RPS6KB2, SKIP, and
TSC2), our results seem to give some support to the hypothesis
of altered calcium dynamics [35,118,119,120,121,122,123,124,
125,126,127], deregulation of insulin signalling [36,41,113,114,
115,116,128,129,130,131,132,133,134,135,136,137,138,139,140,
141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,
156,157,158,159,160,161,162,163,164,165] and the implication
of the Wnt pathway [166,167,168,169,170,171,172,173,174,
175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,
190,191,192,193,194,195,196,197,198,199] in AD pathogenesis.
Figures 10, 11, 12, 13, and 14 illustrate down(up)-regulation of
genes in these signalling pathways (Calcium signalling, Neuroac-
tive ligand receptor pathway, WNT, Phosphatidylinositol and
Insulin signalling, respectively). Figure 15 shows the expression of
probes corresponding to genes for which there are known
associations to synaptic function and neuronal plasticity. We refer
the reader to the supplementary material (File S3) for more
searchable information.
Transcription factors analysis of 1,372-probe signature
reveals significant associations with the EGR/KROX family
of proteins, MAZ, and E2F1
The analysis of the 1,372-probe signature indicates that they
can be linked to putative transcription factors that have been
previously implicated in AD and other neurodegenerative dis-
eases. Using GATHER, we have observed that there is a strong
association with motif V$KROX_Q6 (p-value,0.0004) with 719
out of 1294 genes in our signature; V$MAZ_Q6 (p-value,0.001,
with 1003 genes); and V$E2F1_Q6_01 and V$E2F1_Q3_01 (with
p-values which are smaller than 0.002 and 0.009 respectively). Of
the 1294 genes associated with the 1,372 probes (by GATHER),
more than half of them (656) have a motif for V$E2F1_Q6_01 and
603 have a motif for V$E2F1_Q3_01.
MAZ (MYC-associated zinc finger protein (purine-binding
transcription factor)) , also known as ZF87 and Cys2His2-type
zinc finger transcription factor serum amyloid A activating factor 1
[200], has been previously implicated in Alzheimer’s disease [201]
and as a blood biomarker in schizophrenia [202]. MAZ interacts
with DCC, the receptor for netrin-1, a neuronal survival factor
[203]. Deregulation of cyclin-dependent kinases and abnormal
patterns of E2F1 regulation have also been linked with Alzheimer’s
Figure 8. Heat map of 1,372-probe signature. The probes were
sorted using the memetic algorithm but the samples remain in the
same order than the 50-probe signature.
doi:10.1371/journal.pone.0010153.g008
Table 4. Binding factors related to two groups of genes.
Transcription
Factors Description P value
First group
V$EVI1_04 Ectopic viral integration site 1 encoded factor 0.00069
V$SMAD4_Q6 SMAD family member 4 0.0033
Second Group
V$HNF1_C Hepatic nuclear factor 1 0.0022
V$ACAAT_B Avian C-type CCAAT box 0.0015
The second group has the opposite behaviour, that is, positive correlation with
the severe profile.
The first group has positive correlation with the control profile.
doi:10.1371/journal.pone.0010153.t004
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211,212,213,214,215], and neuronal apoptosis [216,217,218,219,220].
The involvement of the EGR/KROX (immediate early genes)
family of proteins in the pathogenesis of Alzheimer’s disease was
first suggested in [221]. Studies of the behavioural consequences
of stress have shown a link between the activation of the
glucocorticoid receptor mediated response and EGR1, one of
the members of this family [222]. It has been recently proposed
that different members of the EGR/KROX family have dif-
ferent roles in learning and memory and cognitive functions
[223,224,225,226,227,228]. Mutant mice experiments showed
that EGR1/KROX24 is required for the consolidation of long-
term memory, while it is EGR3 the one linked to short-term
memory [229], with EGR2 having perhaps other type of
phenotypic characteristics not yet mapped [230]. In rat hippo-
campus, EGR1 decreases with aging [231]. In a recent study, it
has been shown that initial playbacks of novel songs transiently
increase EGR1 but that the observed response selectively
Figure 9. ‘Common-regulators’ 50-probes’ signature. The figure was obtained using Pathway Studio [569]. The program received as input the
50-probes displayed in Fig. 7 and automatically searched all the known putative common regulators relationships. The highlighted proteins are the 5-
protein signature (IL1- a, TNF-a, IL-3, EGF and GCSF) of [1]. We have also highlighted IL-6 (discussed in [1] in the context of results of classifiers that
also use it) and CSF1, Colony-stimulating factor 1, (macrophage).
doi:10.1371/journal.pone.0010153.g009
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PLoS ONE | www.plosone.org 13 April 2010 | Volume 5 | Issue 4 | e10153Figure 10. Calcium signaling pathway. The upper graph presents the stacked normalized expression values of all the probes involved in the Calcium
signalingwithanupregulationtrend.Thelowergraphanalysesthegenesinvolvedinthepathwaywithadownregulationtendency.Inthesupplementary
material (File S3 sheet ‘Calcium signalling pathway’), the reader will find all the individual gene expression values, normalised and not normalised.
doi:10.1371/journal.pone.0010153.g010
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PLoS ONE | www.plosone.org 14 April 2010 | Volume 5 | Issue 4 | e10153Figure 11. Neuroactive ligand-receptor interaction pathway. The upper graph presents the stacked normalized expression values of all the
probes involved in the pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation
tendency. In the supplementary material (File S3 sheet ‘Neuroactive ligand-receptor’), the reader will find all the individual gene expression values,
normalised and not normalised.
doi:10.1371/journal.pone.0010153.g011
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PLoS ONE | www.plosone.org 15 April 2010 | Volume 5 | Issue 4 | e10153Figure 12. WNT signaling pathway. The upper graph presents the stacked normalized expression values of all the probes involved in the
pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the
supplementary material (File S3 sheet ‘Wnt Signalling’), the reader will find all the individual gene expression values, normalised and not normalised.
doi:10.1371/journal.pone.0010153.g012
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PLoS ONE | www.plosone.org 16 April 2010 | Volume 5 | Issue 4 | e10153Figure 13. Phosphatidylinositol signaling pathway. The upper graph presents the stacked normalized expression values of all the probes
involved in the pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency.
In the supplementary material (File S3 sheet ‘Phosphatidylinositol signalling’), the reader will find all the individual gene expression values,
normalised and not normalised.
doi:10.1371/journal.pone.0010153.g013
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PLoS ONE | www.plosone.org 18 April 2010 | Volume 5 | Issue 4 | e10153habituates after repetition of the stimulus, with a different
expression profile after one day [232] (see [233] and also [234]
in which the homolog of NEFM, one of our biomarkers of reduced
expression with increasing ‘AD severity’ called NF-M, is showed to
be involved in the development and/or maturation of the oscine
song control system).
We found the following connection between EGR/KROX,
E2F1 and MAZ transcription factors that makes their concurrent
finding notable. A recent study of microRNA signature of prion-
induced neurodegeneration [64] has shown that EGR1, E2F1 and
MAZ might be also implicated in the putative deregulation of
immune response related genes by miRNAs via modulation of
transcriptional regulators in scrapie-infected mice. We leave these
findings for the next section of the manuscript where we will
discuss them and present a list of common differentially expressed
genes in these two neurodegenerative processes.
The 1,372-probe signature contains a significant number
of genes differentially expressed that are linked to
synaptic function and neuronal plasticity
The existence of several genes among the most correlated ones
(NRXN1, SV2B, NEFM, etc.,) motivated us to try to identify
which genes were present in the 1,372-probe signature that are
also related to synaptic function and neuronal plasticity. We have
identified 42 probes that can be divided into two groups, those that
seem to be increasingly downregulated with AD severity (CABP1
[235,236,237,238,239,240,241,242,243], CADPS2 [244,245,246,
247,248,249], COLQ [250], DMD [251,252,253,254,255,256],
ELOVL2 [257], FAIM2/LFG [258,259,260,261], GABBR2 [262,
263,264,265], GRIA2/GLUR2 [266,267,268,269,270,271,272,273,
274,275,276,277], ITPR1 [278,279,280,281,282,283], KIAA0528,
LZTS1/FEZ1 [284,285], NEFM, NRG1, NRXN1, NUFIP1 [286,
287,288], PPT1 [289,290,291,292,293,294,295,296,297,298,299,
300,301], PSD3, RAB3B [302,303,304,305,306,307,308,309,310,
311,312,313,314,315,316,317], RIMS2 [318,319,320,321], SHANK2
[322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,
337,338,339,340], SV2B [68,69,341,342,343,344,345,346,347,348,
349,350,351,352,353,354,355,356,357,358,359]) and those that
present an upregulation pattern (CASK [360,361,362], CDK5R1
[363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,
378,379], CHRNA1, CHRNA9, CHRNB3, CTBP2, DLG1/SAP97
[380,381,382,383,384,385,386,387,388], DLGAP2, GABRA5 [389,
390,391,392,393,394], GABRQ [395], GLRA3 [396,397,398],
GRIK3/GLUR7 [399], HOMER3 [400], ICA1 [401], ITGB1
[402,403], MCTP1 [404,405], PPP1CC [406], SNPH [407,408,
409,410,411,412,413,414], SSPN [415], SYNC1, and USH1C
[416,417,418]). The reader can consult the supplementary material
(File S2) for the individual expression patterns of these genes. If, in
agreement with Klemmer et al. [362], consider synapses as the most
complex cellular organelle, with approximately 1500 proteins
interacting in an activity dependent manner, we can argue that we
must be inclusive with our list of references to help other researchers
map the literature of their functions. Our aim is that experts can use
this information to find ways of building novel testable hypotheses of
AD neuronal plasticity impairment in the hippocampus. Our
approach here has been to map what is currently known, and link
it with the current biomedical literature, to facilitate experts that
understand processes in detail.
We have already discussed some of the increasingly downreg-
ulated genes, another important candidate for further study is
NRG1 (Neuregulin 1), a gene that has already been linked to
several neuronal diseases. It is a candidate for susceptibility to
schizophrenia and bipolar disorder (see [419,420,421,422,423,
424,425,426,427,428,429,430,431,432,433,434] and references
therein). There have been reported links of NRG1 with AD.
BACE1 (beta-Site APP-cleaving enzyme) is necessary for the
cleavage of the amyloid-beta precursor protein, and BACE1
participates in the proteolytic processing of NRG1 [435,436], and
there exists some concerns about BACE1 inhibition as a potential
therapeutic intervention due to its interaction with NRG1 and
potential effects on remyelination [437]. In particular, NRG1 has
been reported as a possible biomarker in cerebral spinal fluid,
since its levels have been reported to be significantly increased in
AD. Pankonin et al. suggest that: ‘‘While (NRG1) is not detected in
human serum, a novel neuregulin antagonist activity was identified in human
serum that could have prevented its detection. These results suggest that human
neuregulin is selectively targeted from cortical neurons to white matter
extracellular matrix where it exists in steady-state equilibrium with cerebral
spinal fluid where it has the potential to serve as a biological marker in human
neuronal disorders’’ [438]. NRG1 seems to collaborate with the
ERBB4 receptor, and Li et al. propose that together they control
glutamatergic synapse maturation and plasticity [439]. A single
nucleotide polymorphism in NRG1 has also been associated as a
risk factor to positive symptoms of psychosis in a proportion of
late-onset AD [440]. With this evidence it is clear that NGR1
[439,441,442,443,444,445,446,447] as well as the whole panel pre-
sented here are excellent candidates for further studies due to their
well supported role in synaptic function in health and disease states.
Other biomarkers of interest
We should also mention some other biomarkers that could
be interesting for further studies, including imaging purposes,
like TSPO/PBR (translocator protein (18kDa)) also known as
Mitochondrial Benzodiazepine Receptor (peripheral), thus sup-
porting its current role as a putative imaging biomarker for AD
[448,449,450,451,452,453,454,455], C1S (complement compo-
nent 1, s subcomponent) [456,457,458,459,460,461], FDFT1 (the
squalene synthase gene), which is critical for cholesterol synthesis
[462,463], BMP4 [92,96,464,465], CD68 (as marker of enhanced
lysosomal activity) [450,466,467,468,469,470,471,472], SERTAD2/
TRIP-Br2 [473,474,475], LTF (Lactotransferrin) [476,477,478],
FTL (ferritin, light polypeptide; Ferritin light chain) [479,480,
481,482], MTF1 (Metal-regulatory transcription factor 1) [483,484,
485], GSTA3 (Glutathione S-transferase A3), GSTM4 (Glutathione
S-transferase M4), MT1L (Metallothionein 1L (gene/pseudogene)
[486] (a human-specific truncated protein which may have changed
its function or suppressed it [487]), MT1H (Metallothionein 1H)
[488], MT1F (Metallothionein 1F) [488,489] (Figure 16). These last
three upregulated genes need to be put in concert with other reports
on methallothioneins in AD brains [490,491,492]. Figure 16 shows
the upregulation of Lactotransferrin, FTL (ferritin, light polypeptide;
Ferritin light chain), and the Metallothionein family with increasing
AD severity.
Other probes which present an upregulation trend that we
would like to highlight are BCL2 [493,494], FYCO1 [495,496],
PAX6 [111,497,498,499] (Figure 17), and QKI [500] (Figure 18).
Figure 14. Insulin signaling pathway. The upper graph presents the stacked normalized expression values of all the probes involved in the
pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the
supplementary material (File S3 sheet ‘Insulin signalling’), the reader will find all the individual gene expression values, normalised and not
normalised.
doi:10.1371/journal.pone.0010153.g014
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PLoS ONE | www.plosone.org 20 April 2010 | Volume 5 | Issue 4 | e10153The increase of expression of these probes, together with SOX2, is
intriguing as they are related to differentiation from stem cells and
are considered critical in neurogenesis [501,502,503,504,505,506,
507,508,509,510]. Our results support the combined use of them
in tracking AD progression in this tissue. In addition, we have
previously mentioned the relevance of EGR1 in coordinating a
large number of genes that seem to be differentially expressed in
this study. EGR1 also appears with a marked upregulation in
severe AD patients (we refer to the supplementary material File S2
Sheet ‘1372 norm. +heat map+GO’ for its gene expression profile).
We found that this link is very important, as the homologues of
EGR1, zif268, Egr-1 or ZENK, together with other members of
the EGR family, are consolidating a key role in the neuronal
plasticity in the brain [226,230,511,512,513,514,515,516,517,
518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,
533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,
548,549] and links with AD and cognitive decline progression are
starting to be reported [514,515,550,551,552,553,554].
At the same time, prospective studies should encompass some
other genes which appear downregulated with increasing AD
severity. Top of the list is perhaps LDB2/CLIM1 (LIM domain
binding 2), recently pointed as a marker (with LMO4 [555,556])
of the control program of the development of neuronal subtype
diversity of the cerebral cortex [557]. TRIM36 is another
interesting candidate for further studies [558]. A gene that
shares the same trend of dowregulation is CAMK1G (calcium/
calmodulin-dependent protein kinase IG) [559,560,561,562,
563,564]. When analysing prefrontal cortical tissue from mice
with inducible deletions of BDNF (Brain-derived neurotrofic
factor), Glorioso et al. employed microarray gene expression
profiling to show that there were alterations to early-immediate
genes (including EGR1) and CAMK1G [563]. They conclude
their manuscript stating that: ‘‘while altered BDNF expression may
not represent the primary disturbance in AD, changed expression of, or
altered responsiveness to BDNF (and subsequently decreased SST levels)
may represent a critical feature of Alzheimer’s disease progression.’’
VSNL1 (Visinin-like protein 1) [565], a CA++ sensor protein is
also down-regulated (see Figure 19), a finding which is paralleled
in the work of Youn et al. [566], who found similar changes in
hippocampus.
Figure 15. Genes related to synapse and neuronal plasticity. The upper graph presents the stacked normalized expression values of all the
related probes with an upregulation trend. The lower graph analyses the genes involved with a downregulation inclination. In the supplementary
material (File S3, Sheet ‘Synapse’), the reader will find all the individual gene expression values, normalised and not normalised.
doi:10.1371/journal.pone.0010153.g015
Figure 16. Metallothionein family. Stacked line graph of the probes related to the Metallothionein family in the 1372-probe signature.
doi:10.1371/journal.pone.0010153.g016
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Putative common genes involved in Alzheimer’s disease
and prion-induced neurodegenerative processes
In late 2008, a paper was published in PLoS ONE, shortly after
the publication of our signature for prediction of clinical symptoms
of AD [1] appeared online [64]. In this other contribution, Saba
et al. present a microRNA signature of prion induced neurodegen-
eration [64]. By examination of the promoter regions of putative
microRNA targets, they found that some transcription factor
motifs were significantly enriched, E2F-1 (p-value=6.01610
214),
KROX (p-value=9.34610
214), MAZ (p-value=2.23610
211)
and PAX6 (p-value=1.76610
29). Our identification of EGR1/
KROX-24 and PAX-6 as upregulated with AD progression,
and the identification of motif V$KROX_Q6, V$MAZ_Q6,
V$E2F1_Q6_01, V$E2F1_Q3_01 as enriched in our signature
were two contributing factors that motivated us to explore any
further similarities that we could find.
In [64], an analysis of the predicted target genes of their
microRNA signature, linked with differentially expressed genes
in scrapie-infected mice [65] as well as two other publications
[567,568], led Saba et al. [64] to identify a network of de-regulated
immune response-related genes. Additionally, they identified
the putative transcription regulator genes that are targets of
miRNAs similarly de-regulated. In essence, a possible hierarchy
of deregulations of microRNAs, which, deregulated transcription
factors that then, modify 1282 target genes. A Gene Ontology
analysis also indicated that the ‘‘data sets were found to be in
the significant enrichment for genes involved in cell death, regulation of
the cell cycle, nervous system development and function and cell signalling
pathways.’’
As a consequence, we have investigated if some of the 1,282
putative target genes of the miRNA signature of prion induced
neurodegeneration also appear in our lists. Of those 1,282 genes
we immediately noticed that there were 9 genes listed in our list of
the 50 most correlated genes (Table 3). These genes are BCL11A,
CSF1, DLG5, FOXO1, HBEGF, NRXN1, SERTAD2, SNRK
and ZBTB20. Two of these genes, CSF1 (colony stimulating factor
1 (macrophage)) and HBEGF (heparin-binding EGF-like growth
factor) appear to be conspicuous mediators of cytokine and growth
factor signalling as Figure 9 illustrates (we obtained this network
using Pathway Studio [569] as described in the previous section), and
CSF1 and HBEGF seems to be increasing with AD severity. In
opposition, the probe corresponding to NRXN1 (Neurexin 1,
209915_s_at) has decreasing expression (Figure 20). Although no
connection has been found between NRXN1 and AD yet, this
gene has been implicated in autism [570,571,572,573,574,
575,576], schizophrenia [577,578,579,580,581], nicotine and
Figure 17. Stacked line graph of the probe expression of Ferritin Light Chain, Lactotransferrin, and the Methallothionein family, in
the 1,372-probe signature, that shows an increasing upregualtion with AD severity. The expression of a PAX6 probe shows increasing
upregualtion with AD severity.
doi:10.1371/journal.pone.0010153.g017
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[585]. SERTAD2 (SERTA domain containing 2), mentioned in
the previous section, is also known as Transcriptional regulator
interacting with the PHD-bromodomain 2, TRIP-Br2, a member
of the TRIP-Br family of transcriptional regulators, required for
the transduction of mitogenic signals and the execution of serum-
inducible E2F-mediated cell cycle progression [473]. In our data,
the probe for SERTAD2 is increasing with AD severity. It has also
been reported that overexpression of SERTAD2 is sufficient to
transform murine fibroblasts and promotes tumorigenesis in
athymic nude mice due to the deregulation of the E2F/DP-
transcriptional pathway thanks to the upregulation of the key E2F-
responsive genes [474]. FOXO1 (Forkhead box O1) also appears
upregulated with increasing AD severity, and has been reported as
a negative regulator of EGR1 expression via the activation of the
PI3K/Akt/Forkhead pathway [586]. The expression of FOXO1 is
also induced by E2F1 [587]. The product of this gene has also
been reported as a survival factor in deprivation-induced neuronal
cell death [588,589] (see also the review in [590]). Although
FOXO1 has not been previously implicated in AD, an exception
may exist. van Der Heide et al. describe in [591] how the
Forkhead transcription factors are involved in insulin signalling.
The ‘‘PI3K route’’ is a name given to common signal transduction
cascade that links neuronal survival, synaptic plasticity (and,
as a consequence, learning and memory) [592]. This ‘‘PI3K-Akt-
FOXO1 mechanism’’ and its role in neurons warrant the current
intensive investigation [593,594,595,596,597,598,599,600]. From
this group of 9 genes, seven of them (NRX1, SERTAD2, SNRK,
HBGEF, FOXO1, CSF1, BCL11A) and QKI have been pre-
dicted to be targeted by mmu-mir128 by two or more microRNA
prediction tools. We found this to be a connection that is worth
exploring. Lukiw and Pogue have reported that following
metal-induced reactive oxygen species production (by iron and
aluminium-sulfate at nanomolar concentrations) upregulates miR-
128 in human neural cells in primary culture [601]. They also
report that, together with miR-9, mir-125a, mir-128 is upregulated
in AD brain. In the previously cited reference Lukiw reported that:
‘‘miR-9, miR-124a, miR-125b, miR-128, miR-132 and miR-219 are
abundantly represented in fetal hippocampus, are differentially regulated in aged
brain, and an alteration in specific micro-RNA complexity occurs in Alzheimer
hippocampus.’’
The expression of probes corresponding to PP2A and PP2B
catalytic subunits (i.e. PPP2CA, Protein phosphatase 2 (formerly
2A), catalytic subunit, alpha isoform, and PPP3CA, Protein
phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform,
Calcineurin A1) shows increasing downregualtion with the
progression of AD., see Figure 21. This finding supports a
role for downregulation of PPP2CA, PPP3CA in AD pathology
[619–647].
Finally, in addition to the presence of hyperphosphorylated tau,
theaccumulationofAmyloid-beta (Abeta)peptideinbraintissueisa
hallmark of AD [602]. The identification of the genes involved in
Figure 18. The expression of a QKI probe, like PAX6, also shows increasing upregualtion with AD severity.
doi:10.1371/journal.pone.0010153.g018
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which in turn produces Abeta, is a subject of intense research.
Researchers are currently looking at the alterations of APP cellular
localization and endocytic trafficking as one mechanism that can
modify the processing of APP to Abeta. LRPs are known to regulate
APP’s endocytic trafficking [603,604,605,606], and seem to be a
hub of a number of mounting evidences on processes that link to
cholesterol metabolism and atherosclerosis [607]. In our selected
panelof50proteinswehaveonememberofthisfamily,LRP10(low
density lipoprotein receptor-related protein 10), as one of the most
correlated gene expression profiles. In our list of 1372 gene probe
signature we also have another member of this family, LRP1B (low
density lipoprotein-related protein 1B (deleted in tumors))[608],
While LRP10 appears to be positively upregulated with cognitive
decline an inverse relationship is observed for LRP1B.
LRPs are also known to linked to APP via a mechanism that
involves the alternative splicing of APBB3/Fe65L2 [609,610,611].
Tanahashi and Tabira have proposed that the splicing of APBB3/
Fe65L2 alters the ability to bind with APP and low-density-
lipoprotein-receptor-related protein. They propose that the
secretion of beta-amyloid peptide Abeta40 and Abeta42 is
increased following the overexpression of APBB3, but there are
no visible changes of half-life and maturation of APP, or the
secretion of secreted APP [612]. In our dataset, we observe APBB3
expression being upregulated with the increasing cognitive decline,
following the same pattern of LRP10.
Polymorphisms on these genes have previously been linked to
AD. Tanahashi, Asada and Tabira have reported an association
between a polymorphism in APBB3/Fe65L2 and early-onset AD
[612] (the link between APBB3 and AD is being increasingly
explored, we refer to [613,614,615,616] for further references).
Using 500K SNP microarray technology, Poduslo, Huang and
Spiro have identified haplotypes in LRP1B as significant for
successful aging without cognitive decline in a study involving
individuals that were 85 years old or older, had MMSE scores
greater than 26, no history of dementia in their families, and no
major illnesses (i.e. no cardiovascular problems, diabetes, obesity, or
major cancer diseases) and most of them had normal cholesterol
levels. Their genome-wide association screening compared these
individuals with those that have late-onset AD [617]. Poduslo et al.
have suggested that if the decreased production of Abeta42 in
successful aging is due to the haplotypes they describe, then LRP1B
may be a new target for treatment of AD [608,617], Taken to-
gether these results indicate that integrative bioinformatics analytic
Figure 19. The expression of a probe for VSNL1 (Visinin-like protein-1) shows increasing downregualtion with AD severity. VSNL1, a
neuronal calcium sensor that has received recent attention in AD [636,637,638,639] has also been linked to model systems of schizophrenia, where it
has been found upregulated in hippocampus [640]. A previous result by Schnurra et al. raised the possibility that the redution of VSNL1 expressing
neurons indicate a selective vulnerabilty of these cells, since they observed that VSNL1 expression enhanced hyperphosphorylation of tau protein (in
contrast with nontransfected or calbindin-D28K-transfected cells) [641]. In 2001, Braunewell et al. had already reported the reduction of VSNL1-
immunoactive neurons in the temporal cortex of AD patients as compared with controls [642].
doi:10.1371/journal.pone.0010153.g019
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their role in AD.
Conclusions
This re-analysis of the microarray dataset hippocampal gene
expression contributed by Blalock et al. has shown that there exist a
relatively large number of probes (1,372) that present a clear
pattern of either up or down regulation with increasing AD
severity. The signature reveals alterations in calcium, insulin,
phosphatidylinositol and Wnt-signalling. Among the group of most
correlated gene probes with AD severity we found some linked
to synaptic function, neurofilament bundle assembly, neuronal
plasticity and inflammation.
A transcription factors analysis of 1,372-probe gene expression
signature reveals significant associations with the EGR/KROX
family of proteins, MAZ, and E2F1. The gene homologous of
EGR1, zif268, Egr-1 or ZENK, together with other members of
the EGR family, are consolidating as key players in short and long-
term memory and neuronal plasticity in the brain. We have also
uncovered a large consensus of this gene expression signature with
current genes putatively involved in AD progression. Our results
also indicate a degree of commonality between putative genes
involved in AD and prion-induced neurodegenerative processes
that warrants further investigation.
Materials and Methods
Dataset
In this contribution, we have used a MIAME compliant,
Affymetrix gene expression dataset that is public available and was
contributed by Blalock et al [3] in 2004. We thank the authors of
that publication for making this useful dataset available to the
research community at large allowing further exploration and
reanalysis.
The dataset is available from GEO Dataset Browser, accession
number GDS1297 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE1297). The Affymetrix human GeneChip, HG-
U133A, containing 22,283 targets was used. The dataset is de-
identified and the methods for disease classification, based on
MMSE and NFT scores, are described in full detail by Blalock et al.
in Ref. [3].
The hippocampal samples used by Blalock et al. were obtained
from the autopsy of 31 subjects through the Brain Bank of the
University of Kentucky Alzheimer’s Disease Research Center
(ADRC), Sanders-Brown Center on Aging, University of Ken-
tucky. The ADRC was established in 1985 and in operation since
1989 a pool of research volunteers that have agreed in principle to
be research participants. Participants were asked questions based
on NINCDS/ADRDA criteria [618] to establish their physical
Figure 20. It is possible to observe that one of the probes for NRXN1 (Neurexin 1, 209915_s_at) has decreasing expression with
increasing AD severity. We have found no previous evidence of a connection of NRXN1 and AD, but this gene has been previously implicated in
autism [570,571,572,573,574,575,576], schizophrenia [577,578,579,580,581], nicotine and alcoholism dependence [582,583,584], and mental
retardation [585].
doi:10.1371/journal.pone.0010153.g020
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study. When a mutual agreement existed, the individuals were
visted in their homes to review and sign the informed-consent
document (which was approved by the University of Kentucky
Institutional Review Board). Participants also signed a donor card,
and the visit also aimed to establish their baseline mental-status
testing. Elegibility for the purpose of the study included having a
Mini-Mental State Exam score above 24 [619], passing a series of
cognitive tests, and a previous history of absence of neurological
disease [620], as well as neither substance abuse nor major
psychiatric illnesses. All eligible volunteers were 60 years of age or
older and satisfactorily performed normal activities of daily living.
The Wechsler Adult Intelligence Scale (Vocabulary) was also
applied to exclude significant other medical diseases that could
affect cognition and elegible participants must had no previous
history of head injury with loss of consciousness.
The research participants that were deemed eligible also signed
a form (in addition to the consent document) indicating their
agreement to donate their brain to the Sanders-Brown Center on
Aging. A full description of the methods used can be found in
Brain Donation in Normal Aging Procedures, Motivations, and
Donor Characteristics from the Biologically Resilient Adults in
Neurological Studies (BRAiNS) Project [621].
Blalock et al. [3] categorized the samples in four groups, with a
labelling that indicates different ‘‘levels of severity’’. These labels
were decided based on the MiniMental State Examination (MMSE)
and the Neurofibrillary Tangle count (NFT) of each sample [622].
Samples are then separated in the types ‘Control’, ‘Incipient AD’,
‘Moderate AD’ and ‘Severe AD’. Table 1 of Blalock et al. shows
the mean values of MMSE and NFT for each one of these groups.
In addition, they give the mean Braak stage [623,624,625] for
each one of the groups (2.1 for ‘Control’, 5 for ‘Incipient’, 5.6 for
‘Moderate’ and 5.9 for ‘Severe’). We are grateful to Dr. Blalock
who has kindly given us these values of the Braak stage for each
sample in the dataset. Together with the individual values of
MMSE, NFT, the Braak stage of each sample is included in the
Supplementary Material (File S2 sheet ‘Braak’) section of this
publication.
Methodology
Our analysis method consisted of four steps: abundance
quantization and filtering of probes; a feature selection algorithm
to refine the probe selection; a Jensen-Shannon divergence
computation; and finally, a correlation analysis. Each of these
steps is described below.
As mentioned in the Results section, we only used the samples
labelled as ‘‘Control’’ or ‘‘Severe AD’’ for feature selection, thus
we have a two-class probe/gene selection task. We did not use the
samples labelled as ‘‘Incipient AD’’ or ‘‘Moderate AD’’ for the
probe selection steps. Those samples were only used in the final
step, at the time of computing the correlation of the gene profile,
across all samples, with the Jensen-Shannon divergences computed
for the ‘‘Control’’ and ‘‘Severe’’ classes as explained later in this
section.
For the first step, the quantization of the expression values, as
well as for the initial data pruning, we used Fayyad and Irani’s
algorithm [626]. The heuristic algorithm minimises the feature-
class entropy and discards genes according to the Minimum
Description Length principle. The application of Fayyad and
Irani’s algorithm not only filters several thousand genes, it also
provides thresholds for each probe remaining in the dataset. These
quantized values of gene expression leave us with an instance of a
combinatorial optimization problem, the (a, b)-k-Feature Set problem
[13,627,628].
The (a, b)-k-Feature Set problem is a combinatorial optimisation
problem introduced by Cotta, Sloper and Moscato[628] in 2004
to address the problem of feature selection in high-dimensional
datasets. We solve an instance of this problem numerically using
an integer programming formulation. This approach has been
previously employed to obtain molecular biomarker signatures in
Alzheimer’s Disease [1,629], models of Parkinson disease [630],
prostate cancer [631], electrode selection in EEGs [632], and
elsewhere. To obtain mathematically proven optimal solutions of
the integer programming formulation, the CPLEX commercial
optimization solver was used. As in previous contributions of our
group, we found gene expression signatures corresponding to
values of a maximum and b maximal [1,13,627,628,633]. We
refer the reader to these previous contributions for a detailed
explanation of the methodology.
At this point, we have a selection of 1,372 probes, a set
which we denote as V. For each sample m and probe i [ V, let
fim be its expression value. We now define a probability distribu-
tion function (PDF) for each sample. For sample, m its PDF
P(m)~ pi
(m),Vi [ V
  
, is given by
pi
(m)~
fim P
i [ V fim
We can now compute an average PDF profile for samples in the
‘‘Control’’ and ‘‘Severe AD’’ groups, denoted by PC and PS
respectively. Let C and S be the set of samples with the labels
‘‘Control’’ and ‘‘Severe AD’’ respectively. The average profile
Pc~f p pi
(c),Vi [ Vg, is then:
 p pi
(C)~
 f f i
(C)
P
j [ V f f j
(C) ,Vi [ V,
where
 f fi
(C)~
1
NC
X
m [ C
fim,Vi [ V,
where NC represents the number of samples in class C.  P PS is
analogously defined.
The Jensen-Shannon divergence between two sample PDFs, i.e.
samples l and k (P
(l) and P
(k)) is defined as
JSD P(l),P(k)   
~S
P(l)zP(k)
2
  
{
SP (l)   
2
{
SP (k)   
2
where
Figure 21. The expression of two probes for PPP2CA (Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform,) and
PPP3CA (Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform, Calcineurin A1) show increasing downregualtion
with AD severity. A similar plot exists for PPP3R1 (protein phosphatase 3 (formerly 2B), regulatory subunit B, alpha isoform, Calcineurin subunit B
type 1). This result supports a role for downregulation of PPP2CA, PPP3CA in AD pathology [643,644,645,646,647,648,649,650,651,652,653,654,655,
656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671].
doi:10.1371/journal.pone.0010153.g021
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X N
i~1
Pi:ln Pi ðÞ
S[P] is the Shannon Entropy for a specific PDF sample with N states.
It is well known that the square root of the JSD (sqrtJSD)i sa
metric, which means that for a given set of PDFs the following four
properties are satisfied:
i. sqrtJSD P(l),P(k)   
§0,
ii. sqrtJSD P(l),P(k)   
~sqrtJSD P(k),P(l)   
,
iii. sqrtJSD P(l),P(k)   
~0uP(l)~P(k),
iv. sqrtJSD P(l),P(k)   
zsqrtJSD P(k),P(m)   
§sqrtJSD P(l),P(m)   
:
Once the sqrtJSD between each patient and the two average
profiles ( P PC and  P PS) has been computed, the genes most correlated
with these metrics can be uncovered. We used the Spearman rank
correlation, which is a well-known non-parametric method, and
can thus be used even when the data does not satisfy assumptions
about normality, homoscedasticity and linearity.
Supplementary Material
Supplementary ‘File S1’ provides a glossary of each gene
referenced in this paper including synoms and refrences to iHOP
(http://www.ihop-net.org/).
The results referenced in this manuscript are provided in
supplementary ‘File S2’ and ‘File S3’ in Microsoft Excel format.
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